Successful Treatment of Generalized Pustular Psoriasis With the Interleukin-1-Receptor Antagonist Anakinra: Lack of Correlation With IL1RN Mutations
Authors: Manuelle Viguier
Journal: Annals of Internal Medicine (2010)

Letters6 July 2010Successful Treatment of Generalized Pustular Psoriasis With the Interleukin-1-Receptor Antagonist Anakinra: Lack of Correlation With IL1RN MutationsManuelle Viguier, MD, PhD, Philippe Guigue, Cécile Pagès, MD, Asma Smahi, PhD, and Hervé Bachelez, MD, PhDManuelle Viguier, MD, PhDFrom INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France; INSERM U780, Assistance Publique-Hôpitaux de Paris Hôpital Necker-Enfants Malades, 75015 Paris, France; INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France; INSERM U780, Assistance Publique-Hôpitaux de Paris Hôital Necker-Enfants Malades, 75015 Paris, France; and INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France., Philippe GuigueFrom INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France; INSERM U780, Assistance Publique-Hôpitaux de Paris Hôpital Necker-Enfants Malades, 75015 Paris, France; INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France; INSERM U780, Assistance Publique-Hôpitaux de Paris Hôital Necker-Enfants Malades, 75015 Paris, France; and INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France., Cécile Pagès, MDFrom INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France; INSERM U780, Assistance Publique-Hôpitaux de Paris Hôpital Necker-Enfants Malades, 75015 Paris, France; INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France; INSERM U780, Assistance Publique-Hôpitaux de Paris Hôital Necker-Enfants Malades, 75015 Paris, France; and INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France., Asma Smahi, PhDFrom INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France; INSERM U780, Assistance Publique-Hôpitaux de Paris Hôpital Necker-Enfants Malades, 75015 Paris, France; INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France; INSERM U780, Assistance Publique-Hôpitaux de Paris Hôital Necker-Enfants Malades, 75015 Paris, France; and INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France., and Hervé Bachelez, MD, PhDFrom INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France; INSERM U780, Assistance Publique-Hôpitaux de Paris Hôpital Necker-Enfants Malades, 75015 Paris, France; INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France; INSERM U780, Assistance Publique-Hôpitaux de Paris Hôital Necker-Enfants Malades, 75015 Paris, France; and INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-153-1-201007060-00030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Generalized pustular psoriasis (GPP) is a multisystemic inflammatory disease with disseminated pustular skin involvement that often responds poorly to currently available treatments, including tumor necrosis factor (TNF)-α inhibitors (1). The recent identification of mutations in the IL1RN gene coding for the interleukin (IL)-1 receptor antagonist in an autoinflammatory syndrome with pustular skin involvement provides a rationale to investigate the contribution of the IL-1β pathway to the pathogenesis of GPP (2).Objective: To report the efficacy of the recombinant IL-1 receptor antagonist anakinra and to search for IL1RN gene mutations in 2 patients with GPP.Methods: The IL1RN isoform-1 gene ...References1. Umezawa Y, Ozawa A, Kawasima T, Shimizu H, Terui T, Tagami H, et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res. 2003;295 Suppl 1 S43-54. [PMID: 12677432] CrossrefMedlineGoogle Scholar2. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360:2426-37. [PMID: 19494218] CrossrefMedlineGoogle Scholar3. Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol. 2007;149:217-25. [PMID: 17590166] CrossrefMedlineGoogle Scholar4. Mee JB, Cork MJ, di Giovine FS, Duff GW, Groves RW. Interleukin-1: a key inflammatory mediator in psoriasis? Cytokine. 2006;33:72-8. [PMID: 16460958] CrossrefMedlineGoogle Scholar5. Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, Weng N, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 2007;204:2603-14. [PMID: 17908936] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France; INSERM U780, Assistance Publique-Hôpitaux de Paris Hôpital Necker-Enfants Malades, 75015 Paris, France; INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France; INSERM U780, Assistance Publique-Hôpitaux de Paris Hôital Necker-Enfants Malades, 75015 Paris, France; and INSERM U976, Université Denis-Diderot (Paris 7), Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, 75010 Paris, France.Disclosures:Consultancies: M. Viguier (Janssen-Cilag), H. Bachelez (Abbott, Centocor, Janssen-Cilag, Merck Serono, Schering-Plough, Wyeth Pharmaceuticals). Grants received: H. Bachelez (Roche). PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe IL-1 cytokine family as custodians of barrier immunityA review of IL-36: an emerging therapeutic target for inflammatory dermatosesIs psoriasis therapy an art based on experience?Therapeutic potential of targeting interleukin‐1 family cytokines in chronic inflammatory skin diseasesThe interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic studyAnakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)*Off-Label studies on anakinra in dermatology: a reviewAutoinflammatory disordersPustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic OptionsGeneralized Pustular Psoriasis: Divergence of Innate and Adaptive ImmunityIL-1 Family Antagonists in Mouse and Human Skin InflammationAdvances in understanding of Netherton syndrome and therapeutic implicationsGeneralized pustular psoriasis—Dawn of a new era in targeted immunotherapyBiologics in the treatment of pustular psoriasisScoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescentsDermatologic and Dermatopathologic Features of Monogenic Autoinflammatory DiseasesAn update on generalized pustular psoriasisAutoinflammatory Disorders: A Review and Update on Pathogenesis and TreatmentInterleukin-36 in Infectious and Inflammatory Skin DiseasesPustulosis palmoplantar: características epidemiológicas, clínicas y genéticas de una serie de 41 casosLack of association of the IL-1RN and IL-10 polymorphisms with risk of psoriasis: A meta-analysisPustular Forms of Psoriasis Related to AutoinflammationA small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trialSystemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic ReviewGeneralized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic reviewGeneralized pustular psoriasis: a review and update on treatmentUnopposed IL-36 Activity Promotes Clonal CD4+ T-Cell Responses with IL-17A Production in Generalized Pustular PsoriasisPustular psoriasis and related pustular skin diseasesPsoriasis: from Pathogenesis to Targeted TherapiesPustular PsoriasisPsoriasis: a mixed autoimmune and autoinflammatory diseaseInflammasome activation by nucleic acids and nucleosomes in sterile inflammation… or is it sterile?IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasisPotential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin DiseasesJuvenile generalized pustular psoriasis is a chronic recalcitrant disease: an analysis of 27 patients seen in a tertiary hospital in Johor, MalaysiaHuman S100A7 Induces Mature Interleukin1α Expression by RAGE-p38 MAPK-Calpain1 Pathway in PsoriasisWhat do we know about palmoplantar pustulosis?Pustulosis palmaris et plantaris: pathogenetic, clinical, and epidemiological featuresUpdate on psoriasis immunopathogenesis and targeted immunotherapyImiquimod Treatment Causes Systemic Disease in Mice Resembling Generalized Pustular Psoriasis in an IL-1 and IL-36 Dependent MannerIMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasomeMonogenic autoinflammatory diseases: CytokinopathiesTreatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumabA Review and Proposed Approach to the Neutrophilic Dermatoses of ChildhoodAutoinflammatory SyndromesAutoinflammatory Syndromes: Relevance to Inflammatory Skin Diseases and Personalized MedicineGenetics of PsoriasisTolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide surveyMutation analysis of the IL36RN gene in Chinese patients with generalized pustular psoriasis with/without psoriasis vulgarisDifferential developmental requirement and peripheral regulation for dermal Vγ4 and Vγ6T17 cells in health and inflammationPartial clinical response to anakinra in severe palmoplantar pustular psoriasisPustular Psoriasis in Childhood and Adolescence: A 20-Year Single-Center ExperienceAutoinflammatory syndromes for the dermatologistPsoriasis heritability: 125 years and countingClinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, MalaysiaIs it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutationsPustular psoriasis in a patient with Turner syndrome: profile of serum cytokine levelsBiological therapies for psoriasisMutations in IL36RN in Patients with Generalized Pustular PsoriasisFirst Clinical Description of an Infant With Interleukin-36-Receptor Antagonist Deficiency Successfully Treated With AnakinraAutoinflammatory Pustular Neutrophilic DiseasesAutoinflammation: From monogenic syndromes to common skin diseasesPrimary immunodeficiencies: A rapidly evolving storyNeue HautkrankheitenDissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patientsDermatosis neutrofílicasGenetic support for the role of the NLRP3 inflammasome in psoriasis susceptibilityPsoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: The Mayo Clinic experience, 1998 to 2010Pityriasis amiantacea: a distinctive presentation of psoriasis associated with tumour necrosis factor-α inhibitor therapyDermatoses neutrophiliquesIndications et modalités d'utilisation des antagonistes de l'interleukine (IL)-1 dans les dermatoses inflammatoiresCathelicidin LL-37: a defense molecule with a potential role in psoriasis pathogenesisPsoriasis pustuleuxAutoinflammatory SyndromesIL-1 Receptor Signaling Is Required at Multiple Stages of Sensitization and Elicitation of the Contact Hypersensitivity ResponseQuoi de neuf en recherche dermatologique ?Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular PsoriasisIL-1 Receptor Accessory Protein-Ig/IL-1 Receptor Type II-Ig Heterodimer Inhibits IL-1 Response More Strongly than Other IL-1 Blocking Biopharmaceutical AgentsCytosolic DNA Triggers Inflammasome Activation in Keratinocytes in Psoriatic LesionsIL-1 Inhibition in Cryopyrin-Associated Periodic Syndrome and Beyond: A Million Dollar Question about the Injection Schedule of Biotherapies 6 July 2010Volume 153, Issue 1Page: 66-67KeywordsC-reactive proteinsDNA sequencingErythemaFeversMutationPathogenesisPsoriasisStaphylococcus aureus ePublished: 6 July 2010 Issue Published: 6 July 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...